Show Cart
PipelineReview.com
Home
My cart / Checkout
Contact Us
Home
News Channels
Antibodies
DNA, RNA & Cells
Protein & Peptides
Small Molecules
Vaccines
More News
Reports
All Products
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells & NK Cells
Immuno-Oncology
mRNA Vaccines & Therapeutics
Pipeline Database
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Proteins & Peptides
Vaccines
FREE reports
Offers
Press Room
About Us
Home
News Channels
Antibodies
DNA, RNA & Cells
Protein & Peptides
Small Molecules
Vaccines
More News
Reports
All Products
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells & NK Cells
Immuno-Oncology
mRNA Vaccines & Therapeutics
Pipeline Database
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Proteins & Peptides
Vaccines
FREE reports
Offers
Press Room
About Us
Home
News Channels
DNA, RNA & Cells
DNA RNA and Cells
28 Nov 2018
Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy Clinical Candidate for Multiple Solid Tumor Indications
28 Nov 2018
FDA Clears SpinalCyte IND Application for Universal Donor Cell Therapy to Treat Lower Back Pain
28 Nov 2018
Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
28 Nov 2018
Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
28 Nov 2018
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
27 Nov 2018
Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome
27 Nov 2018
Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease
27 Nov 2018
DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial
27 Nov 2018
Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
27 Nov 2018
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
26 Nov 2018
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
26 Nov 2018
Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform In Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019
23 Nov 2018
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
21 Nov 2018
Kolon TissueGene Doses First Patient in US Phase III Clinical Trial
21 Nov 2018
Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome (CRS) and Neurotoxicity
19 Nov 2018
Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I)
19 Nov 2018
BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
19 Nov 2018
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
19 Nov 2018
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
16 Nov 2018
Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study
16 Nov 2018
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
14 Nov 2018
Virion Biotherapeutics Demonstrates Preclinical Proof-of-Concept for First Therapeutic Interfering Particle Candidate in Respiratory Virus Infections
13 Nov 2018
Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
13 Nov 2018
Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500
13 Nov 2018
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
Page 5 of 150
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Currencies
Australian dollar $
British pound £
Canadian dollar $
Danish krone kr
Euro €
Japanese yen ¥
Swedish krona kr
Swiss franc CHF
United States dollar $
Shopping cart
Cart empty
Please wait
Latest report
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
Featured Products
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
Latest Target Pipeline
Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018
Currencies
Australian dollar $
British pound £
Canadian dollar $
Danish krone kr
Euro €
Japanese yen ¥
Swedish krona kr
Swiss franc CHF
United States dollar $
Shopping cart
Cart empty
Please wait
Latest report
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
Featured Products
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
Latest Target Pipeline
Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018
La Merie Biologics
FREE Weekly News Bulletin
Sign Up
2017 Sales of
Antibodies & Proteins
Get it now
New Product Alert
For La Merie Publishing
Sign Up
Top